组织工程与重建外科杂志
組織工程與重建外科雜誌
조직공정여중건외과잡지
JOURNAL OF TISSUE ENGINEERING AND RECONSTRUCTIVE SURGERY
2013年
4期
195-198,203
,共5页
刘静%韩冬梅%王志东%郑晓丽%丁丽%朱玲%薛梅%阎洪敏%郭子宽%王恒湘
劉靜%韓鼕梅%王誌東%鄭曉麗%丁麗%硃玲%薛梅%閻洪敏%郭子寬%王恆湘
류정%한동매%왕지동%정효려%정려%주령%설매%염홍민%곽자관%왕항상
脐带间充质干细胞%遗传性痉挛性截瘫%疗效
臍帶間充質榦細胞%遺傳性痙攣性截癱%療效
제대간충질간세포%유전성경련성절탄%료효
Umbilical cord mesenchymal stem cells%Hereditary spastic paraplegia%Effectiveness
目的观察脐带间充质干细胞（UC-MSC）治疗遗传性痉挛性截瘫（HSP）的临床疗效及安全性。方法2010年9月及2011年4月，分别给予一HSP家系父子2人行UC-MSC鞘内注射治疗，两个疗程，每次1×106 cells/Kg，每周1次，4次为1个疗程。采用改良的Ashworth肌张力分级标准（MAS）、国际合作共济失调评分量表（ICARS）及日常生活量表（ADL），对患者治疗前后神经功能、日常生活能力进行评定。结果第一疗程结束1个月与治疗前比较，2人MAS分级、ICARS及ADL评分均降低，两人行走站立稳定性及言语流利程度较治疗前改善；第二疗程结束后1个月与该疗程治疗前比较，2人ICARS及ADL评分降低，儿子肌张力进一步降低，父亲双上肢共济失调减轻。2人治疗后均未见明显不良反应发生。末次治疗结束后随访20个月，父、子俩分别于第二疗程治疗结束7个月及8个月后，症状继续加重。结论 UC-MSC鞘内注射治疗是安全的，可在一定时间内一定程度上减轻患者临床症状，提高患者生活质量，延缓疾病进展，但疗效不能持久。
目的觀察臍帶間充質榦細胞（UC-MSC）治療遺傳性痙攣性截癱（HSP）的臨床療效及安全性。方法2010年9月及2011年4月，分彆給予一HSP傢繫父子2人行UC-MSC鞘內註射治療，兩箇療程，每次1×106 cells/Kg，每週1次，4次為1箇療程。採用改良的Ashworth肌張力分級標準（MAS）、國際閤作共濟失調評分量錶（ICARS）及日常生活量錶（ADL），對患者治療前後神經功能、日常生活能力進行評定。結果第一療程結束1箇月與治療前比較，2人MAS分級、ICARS及ADL評分均降低，兩人行走站立穩定性及言語流利程度較治療前改善；第二療程結束後1箇月與該療程治療前比較，2人ICARS及ADL評分降低，兒子肌張力進一步降低，父親雙上肢共濟失調減輕。2人治療後均未見明顯不良反應髮生。末次治療結束後隨訪20箇月，父、子倆分彆于第二療程治療結束7箇月及8箇月後，癥狀繼續加重。結論 UC-MSC鞘內註射治療是安全的，可在一定時間內一定程度上減輕患者臨床癥狀，提高患者生活質量，延緩疾病進展，但療效不能持久。
목적관찰제대간충질간세포（UC-MSC）치료유전성경련성절탄（HSP）적림상료효급안전성。방법2010년9월급2011년4월，분별급여일HSP가계부자2인행UC-MSC초내주사치료，량개료정，매차1×106 cells/Kg，매주1차，4차위1개료정。채용개량적Ashworth기장력분급표준（MAS）、국제합작공제실조평분량표（ICARS）급일상생활량표（ADL），대환자치료전후신경공능、일상생활능력진행평정。결과제일료정결속1개월여치료전비교，2인MAS분급、ICARS급ADL평분균강저，량인행주참립은정성급언어류리정도교치료전개선；제이료정결속후1개월여해료정치료전비교，2인ICARS급ADL평분강저，인자기장력진일보강저，부친쌍상지공제실조감경。2인치료후균미견명현불량반응발생。말차치료결속후수방20개월，부、자량분별우제이료정치료결속7개월급8개월후，증상계속가중。결론 UC-MSC초내주사치료시안전적，가재일정시간내일정정도상감경환자림상증상，제고환자생활질량，연완질병진전，단료효불능지구。
Objective To observe the safety and effectiveness of umbilical cord mesenchymal stem cells(UC-MSC) in the treatment of hereditary spastic paraplegia(HSP) from a familial father and son. Methods In September 2010 and April 2011, a familial father and son with HSP were given UC-MSCs by intrathecal injection for 2 courses, at a dose of 1x106/kg, once a week, 4 times as a course. Modified Ashworth Scale(MAS), International Cooperative Ataxia Rating Scale(ICARS) and Activity of Daily Living Scale (ADL) were used to evaluate patients' neural function and quality of daily life before and after cell therapy. Results Comparing their MAS grading, ICARS and ADL scores one month after the first course therapy with those before therapy, it is found that MAS grading, ICARS and ADL scores were decreased, their stability of walking and standing, as well as verbal fluency were improved. Comparing their ICARS and ADL scores one month after the second course therapy with those before the second course therapy, it is found that their ICARS and ADL scores were decreased, son ’s muscular tension was further reduced, and father’s ataxia was relieved. No side effect was observed in both of them. A follow-up of 20 months after the second course therapy showed that the father and son ’s symptoms progressed respectively at the time of 7 months and 8 months after all therapy. Conclusion Intrathecal injection of UC-MSCs is safe and can ameliorate clinical symptoms, improve life quality of HSP patients to some extent within a certain period, and slow down disease progression, but efficacy can not permanently maintain.
